Related by context. All words. (Click for frequent words.) 74 including eniluracil ADH 73 IMA# 72 oral prodrug 72 FOLOTYN ® 72 sodium thiosulfate STS 71 CBLC# 71 PSMA ADC 71 Proxinium TM 71 Archexin 71 Phase 2b Clinical Trial 71 Cloretazine 70 receptor tyrosine kinase inhibitor 70 Aplidin 70 NP2 Enkephalin 70 mertansine 70 Phase Ib II 70 alvespimycin 70 CYT# potent vascular disrupting 70 SNT MC# 70 HGS ETR2 70 Cloretazine ® 70 MCSP respectively 70 CD# CEA 70 Vicinium TM 70 phase IIa clinical 70 MKC# MT 70 trastuzumab DM1 T DM1 70 huC# DM4 70 Panzem R 70 Azedra 70 CCR9 antagonist 70 forodesine 69 HGS ETR1 69 CB2 selective receptor agonist 69 CEQ# 69 Phase 1b clinical trials 69 rALLy clinical trial 69 Cannabinor 69 Carfilzomib 69 Onconase 69 kidney urologic 69 Annamycin 69 mapatumumab 69 targeted radiotherapeutic 69 tubulin inhibitor 69 investigational humanized monoclonal antibody 69 YONDELIS 69 metaglidasen 69 antibody MAb 69 Phase III Pivotal 69 Solazed TM 69 Allovectin 7 R 69 riociguat 69 Panzem R NCD 69 telomerase therapeutic 69 HGS ETR1 mapatumumab 69 CR# vcMMAE 69 novel VDA molecule 69 acyclovir Lauriad R 69 Alocrest 69 HuLuc# 69 OncoVex 69 ONCONASE R 69 AAG geldanamycin analog 68 NPC 1C 68 multicenter Phase II 68 BrachySil TM 68 GLP toxicology studies 68 docetaxel Taxotere ® 68 Cloretazine R 68 PEG SN# 68 MKC# MKC# PP 68 MAGE A3 ASCI 68 Aflibercept 68 phase Ib 68 Panzem 68 OMP #M# 68 Phase Ib clinical trials 68 Phase IIb clinical trials 68 HuMax EGFr 68 #I TM# 68 Nanobody 68 Cetrorelix 68 apoptosis inducer 68 initiated Phase Ib 68 AEG# 68 cMET 68 acetonide FA 68 cannabinor 68 #D#C# 68 Trofex 68 Phase #b/#a clinical 68 IRX 2 68 ARRY # 68 phase IIb clinical 68 PANVAC VF 68 Pivotal Phase III 68 Ceflatonin R 68 therapeutic monoclonal antibody 68 MGCD# [001] 68 TRO# 68 ELACYT 68 biased ligand 68 tramiprosate Alzhemed TM 68 Tyrima 68 JAK inhibitor 68 ATL# [001] 68 Golimumab 68 SinuNase TM 68 BENLYSTA TM 68 PDX pralatrexate 68 pharmacokinetic PK study 68 OvaRex ® MAb 68 JAK inhibitors 67 Enzastaurin 67 telomerase inhibitor drug 67 Proellex TM 67 MGd 67 oral picoplatin 67 Cethrin R 67 IAP inhibitor 67 deforolimus 67 DXL# 67 Zemiva TM 67 triphendiol 67 IMC A# 67 metastatic colorectal 67 Tesetaxel 67 Solazed 67 phase IIb trial 67 fosbretabulin 67 OHR/AVR# 67 Phase III Clinical Trials 67 Zalypsis 67 compound INCB# 67 Xanafide 67 HQK 67 immatics 67 CORT # 67 docetaxel Taxotere R 67 histone deacetylase HDAC inhibitor 67 CD# monoclonal antibody 67 anticancer compound 67 Traficet EN 67 lorvotuzumab mertansine 67 OXi# 67 Combination REOLYSIN R 67 PI3K/Akt pathway inhibitor 67 MEK inhibitor RDEA# 67 Tarvacin TM 67 Atiprimod 67 Phase #b/#a 67 ENMD # 67 MOZOBIL 67 preclinical efficacy 67 ALN TTR 67 PrevOnco ™ 67 Factor VIIa 67 antibody MT# 67 Myocet 67 cancer immunotherapies 67 Chemophase 67 SinuNase ™ 67 Omacetaxine 67 lintuzumab SGN 67 QNEXA ® 67 oncolytic virus therapies 67 Pazopanib 67 Hsp# Inhibitor 67 YONDELIS R 67 Fx #A 67 TKB# 67 Civacir 67 BRIM2 67 Trofex TM 67 paclitaxel poliglumex 67 drug GAP #B# 67 IMC #B 67 gefitinib Iressa 67 LymphoStat B TM 67 Epratuzumab 67 CRD5 67 GTC recombinant human 67 CRMD# 67 preclinically 67 hypoxia activated prodrug 67 torezolid phosphate 67 ADVANCE PD 67 OvaRex R 67 Personalized Immunotherapy 66 Squalamine 66 AKT inhibitor 66 BNC# 66 TLK# 66 midstage trials 66 Protexia ® 66 cathepsin K inhibitor 66 IND submission 66 PXD# 66 ospemifene 66 PSN# [002] 66 Phase III Clinical Trial 66 GRN# 66 CA4P 66 virus HCV protease inhibitor 66 multicenter Phase 66 Phase Ib clinical 66 Curaxin CBLC# 66 Bayer HealthCare Onyx Pharmaceuticals 66 phase Ib clinical 66 selective immunoproteasome inhibitor 66 Dacogen injection 66 advanced carcinoid 66 Initiates Phase II 66 SUCCEED trial 66 radiotherapeutic 66 GW# [003] 66 BiovaxID TM 66 GALNS 66 Initiates Enrollment 66 Ocrelizumab 66 anti amnesic 66 axitinib 66 Ceflatonin 66 Diamyd ® 66 motesanib 66 NTDDS 66 GEM OS2 66 Azedra TM 66 recombinant PSMA vaccine 66 IIa clinical trials 66 AQ4N 66 adecatumumab 66 antisense inhibitors 66 candidates Augment ™ 66 Allovectin 7 66 Completes Patient Enrollment 66 ganetespib 66 vosaroxin 66 PEGPH# 66 Symadex 66 catheter occlusion 66 ESBA# 66 PDE4 inhibitor 66 Phase IIIb clinical 66 Xcytrin R 66 entinostat 66 non nucleoside HCV 66 novel therapeutic antibodies 66 Aganocide 66 gastro intestinal inflammation 66 ulimorelin 66 INS# [001] 66 Genasense ® oblimersen 66 apricitabine ATC 66 HGS# 66 Vascugel 66 ACV1 66 NS5A 66 Phase 1a clinical 66 Aviptadil 66 liposomal formulation 66 Sapacitabine 66 OncoGel 66 Phase Ib study 66 BZL# 66 Prodarsan ® 66 OMP #R# 66 CRLX# 66 ALN VSP 66 elacytarabine 66 ThermoDox R 66 Triapine R 66 anticancer compounds 66 PLK1 SNALP 66 leading oral taxane 66 Elafin 66 EndoTAG TM -1 66 Prodarsan R 66 Interferon Gamma 66 IgG1 monoclonal antibody 66 isoform selective 66 PhG alpha 1 66 XmAb# 66 mitogen activated ERK kinase 66 Lixivaptan 66 TRV# [001] 66 MT#/MEDI-# 66 PORxin TM 66 oral deforolimus 66 ATL/TV# 66 BRIM3 66 TPI ASM8 66 THR beta agonist 66 TNFerade TM 65 atacicept 65 tafamidis 65 Afatinib 65 midstage clinical 65 depsipeptide 65 CCX# 65 lucinactant 65 neratinib 65 relapsing remitting MS RRMS 65 Pertuzumab 65 Successfully Completes Phase 65 sorafenib tablets 65 Ozarelix 65 CTAP# Capsules 65 Initiate Clinical Trial 65 TBC# 65 selective androgen receptor modulator 65 ALK inhibitors 65 GVAX ® 65 IIa clinical 65 vascular disrupting agent 65 elotuzumab 65 Dapagliflozin 65 sarcoma melanoma 65 Capesaris 65 Neulasta ® 65 Zybrestat 65 Glufosfamide 65 rxRNA 65 humanised monoclonal antibody 65 MEK inhibitor 65 Microplasmin 65 PHX# 65 Nicole Onetto MD 65 Curaxin 65 trastuzumab DM1 65 Surfaxin LS 65 Nanobody ® 65 Darinaparsin 65 Dacogen decitabine 65 agonistic human 65 LymphoStat B belimumab 65 Quinamed 65 lenalidomide Revlimid R 65 Aclidinium 65 GRNVAC1 65 R#/MEM # 65 TRAIL receptor antibodies 65 OncoVEX GM CSF 65 Achieves Primary Endpoint 65 opioid induced bowel dysfunction 65 bardoxolone 65 Initiates Clinical 65 ANAVEX #-# [001] 65 BENLYSTA ® 65 Phase 2a Clinical Trial 65 Meets Primary Endpoint 65 XP# XP# 65 retaspimycin 65 oral taxane 65 malignant ascites 65 BrachySil 65 oral antiviral 65 IL# PE#QQR 65 erlotinib Tarceva ® 65 CINTREDEKIN BESUDOTOX 65 Phase IIB 65 eniluracil 65 protein tyrosine phosphatase 1B 65 next generation URAT1 65 lumiliximab 65 ZEVALIN ® 65 Augment TM 65 TACI Ig 65 PROSTASCINT R 65 candidate deforolimus 65 PGL# 65 Angiocept 65 Virulizin ® 65 carcinoma HCC 65 aurora kinase 65 tiapamil 65 mGluR5 negative 65 LEP ETU 65 Reports Preclinical Data 65 ICA # 65 Pivotal Phase 65 drug pipeline TAFA# 65 demonstrated antitumor activity 65 Amrubicin 65 cilengitide 65 ASONEP 65 Bezielle 65 Aplidin R 65 DPX Survivac 65 biliary tract cancer 65 thalidomide Thalomid 65 HCD# [002] 65 Evoltra ® 65 SAR# [004] 65 novel peptide 65 Pivotal Study 65 Actimmune ® 65 TOCOSOL Camptothecin 65 Virulizin R 65 DCVax R 65 ixabepilone 65 pralatrexate injection folate analogue 65 pan HDAC inhibitor 65 monoclonal antibody conjugated 65 CCR5 mAb 65 Marqibo TM 65 oral methylnaltrexone 65 lexidronam injection 65 Sym# 65 generation URAT1 inhibitor 65 Kahalalide F 65 novel anticancer 65 talactoferrin 65 systemically administered 65 drug ISA# 65 INCB# [001] 65 Elagolix 65 TG# [003] 65 Reolysin 65 Xelox 65 indibulin 65 phase IIa 65 potent antiproliferative 65 vaccine GRNVAC1 65 candidate XP# 65 vidofludimus 65 Tectin TM 65 VitiGam 65 MYDICAR ® 65 VNP#M 65 Zemiva ™ 65 delta opioid receptor 65 Azixa MPC 65 doxorubicin Transdrug ® 65 GAP #B# 65 optimal dosing regimens 65 ALN PCS 65 Shigamabs ® 65 Hepatocellular Carcinoma HCC 65 investigational monoclonal antibody 65 acadesine 65 oral ridaforolimus 65 Novolimus 65 obatoclax 65 monoclonal antibody MAb 65 BRAF inhibitor 65 budesonide foam 65 myelofibrosis polycythemia vera 65 velafermin 65 HuMax TAC 65 R sorafenib tablets 65 eprotirome 64 HyACT 64 pertuzumab 64 adrenergic regulation 64 Testosterone MDTS ® 64 ALGRX 64 recurrent metastatic ovarian cancer 64 2 inhibitor CYT# 64 PNT# 64 Romidepsin 64 Pivotal Phase II 64 G#DT 64 pain palliation 64 RGB # 64 Phase 1b 64 ThermoDox ® clinical 64 Phase IIb trials 64 PORxin TM platforms 64 SUTENT ® 64 Diabetic Macular Edema DME 64 AeroLEF TM 64 JAK1 64 refractory gout 64 BioNumerik 64 drug conjugate 64 candidate CRLX# 64 dacetuzumab SGN 64 PKC# 64 HDACi 64 PEGylated interferon beta 1a 64 Cand5 64 trial evaluating PRX# 64 Phase IIa trials 64 Phase 2a clinical trials 64 histone deacetylase inhibitor 64 CINQUIL 64 albiglutide 64 Aurexis 64 Kamada AAT 64 brivaracetam 64 Sudhir Agrawal D.Phil 64 multicenter Phase III 64 Rigel R# 64 Safinamide 64 imetelstat GRN#L 64 JAK2 inhibitors 64 tezampanel NGX# 64 Apaziquone 64 bevacizumab Avastin ® 64 Hedgehog Pathway Inhibitor 64 2 methoxyestradiol 64 Pirfenidone 64 oral JAK1 64 cediranib 64 Vitaxin 64 Daclizumab 64 Temsirolimus 64 E2F Decoy 64 PNP inhibitor 64 compound PMX # 64 HCV protease inhibitors 64 ularitide 64 assessing T DM1 64 Tumour Vascular Disrupting Agent 64 LUX Lung 64 orally inhaled migraine 64 novel histone deacetylase 64 overactive bladder AA# 64 EGFR HER2 64 Initiate Phase 64 farletuzumab 64 Fibrillex TM 64 histone deacetylase HDAC 64 huN# DM1 64 TELINTRA 64 EndoTAG 64 PRTX 64 alkylating agent 64 seliciclib CYC# 64 EVIZON TM 64 targeting miR 64 ocular formulation 64 Elotuzumab 64 Pimavanserin 64 product platforms AZX# 64 Pivotal Clinical Trial 64 Triolex 64 cobiprostone 64 Vidofludimus 64 CINOD 64 Romiplostim 64 II Clinical Trial 64 Advaxis Phase 64 Stedivaze 64 candidate TNFerade biologic 64 sunitinib malate 64 corticosteroid dexamethasone 64 Aurora Kinase 64 UPLYSO 64 TKM PLK1 64 AZX# 64 enzastaurin 64 HDAC Inhibitor 64 muscarinic receptor agonist 64 PRT# 64 nalbuphine ER 64 Insegia 64 polysaccharide polymer 64 fibrotic disease 64 Thiarabine 64 Varespladib 64 herpetic keratitis 64 ALTROPANE R 64 BLA filing 64 adecatumumab MT# 64 Pharmos pipeline 64 diarrhea predominant irritable 64 personalized cellular immunotherapy 64 Atu# 64 sunitinib Sutent 64 Alpharadin 64 Phase IIIb 64 TELCYTA 64 multi kinase inhibitor 64 Therapeutic Vaccine 64 Pivotal Trial 64 plasma kallikrein inhibitor 64 Phase 2b Trial 64 PrevOnco 64 afamelanotide 64 DEB# 64 sitaxsentan 64 Nexavar sorafenib 64 Antitumor Activity 64 evaluating Prochymal 64 Soliris TM eculizumab 64 evaluating tivozanib 64 KNS # 64 RiVax 64 Intravenous CP 64 StaphVAX R 64 TYZEKA 64 telomerase inhibitor 64 relapsed MM 64 dasatinib Sprycel ® 64 Advanced Renal Cell 64 mTOR inhibition 64 EP #R 64 Panzem NCD 64 RhuDex ® 64 Cloretazine R VNP#M 64 recurrent glioblastoma multiforme 64 MGN# 64 Cinryze ™ 64 Phase Ib 64 delipidation 64 NXL# 64 granted Ortec 64 Lisofylline LSF 64 randomized Phase IIb 64 PEGylated 64 microtubule inhibitor 64 Phase IIb III 64 DNA intercalator 64 Epidermal Growth Factor Receptor 64 delivers fluocinolone acetonide FA 64 motexafin gadolinium Injection 64 hoFH 64 Thiovir 64 initiated Phase 1b 64 proteasome inhibitor 64 thetreatment 64 CCR1 64 P#X# antagonist 64 LHRH antagonist 64 PF # [002] 64 Immunotherapeutic 64 orally administered inhibitor 64 Telik logo TELINTRA 64 ongoing Phase 1b 64 Ultrafast Insulin 64 uricase 64 panitumumab Vectibix 64 CIMZIA TM 64 Commences Phase 63 Alfacell proprietary ribonuclease 63 Onalta ™ 63 Vorinostat 63 Friedreich Ataxia FRDA 63 Irinotecan 63 candidates Azedra TM 63 stated Michelle Berrey 63 mGluR2 NAM 63 phase IIb 63 DAVANAT 63 BAY #-# 63 Blinatumomab 63 PREOS R 63 ruxolitinib 63 hormone LHRH antagonist 63 Fodosine 63 ZFP Therapeutic 63 NeoLipid R 63 AP# [003] 63 rindopepimut 63 glucokinase activator 63 pancreatic colon 63 ARIKACE ™ 63 Vandetanib 63 Kinase Inhibitor 63 Angiolix 63 iobenguane 63 PEP# [003] 63 APEX PD 63 acyclovir Lauriad ® 63 Protexia R 63 Evoltra TM 63 Phase 2a trial 63 olaparib 63 Exherin 63 ZOLINZA 63 IIa trial 63 intranasal formulation 63 cardio renal 63 EGS# 63 topically applied SEPA 63 pharmacokinetics pharmacodynamics 63 phase IIb study 63 Perifosine 63 oral proteasome inhibitor 63 Amplimexon 63 Bioral Amphotericin B 63 Phase III ADT 63 Removab 63 Entereg R 63 IMiDs R 63 Locteron ® 63 Phase IIa trial 63 5 HT2A inverse 63 antiangiogenic agents 63 RSD# oral 63 Alexza Staccato 63 telaprevir VX 63 pharmacogenomic translational research 63 Pafuramidine 63 EOquin TM 63 Zingo TM 63 oral rivaroxaban 63 HepeX B TM 63 IMiDs ® compound 63 JAK2 Inhibitor 63 INSPIRE Trial Phase III 63 vinca alkaloid 63 vascular disrupting 63 alemtuzumab Campath 63 protein kinase inhibitor 63 Resten NG 63 small molecule thrombopoietin 63 Tß4 63 Pharmos proprietary 63 tremelimumab 63 HepeX B 63 includes TOLAMBA TM 63 DOS# 63 Anidulafungin 63 ALN HPN 63 radiation sensitizer 63 Initiates Clinical Trial 63 pharmacokinetic PK 63 XL# anticancer compounds 63 MKC# 63 NEUGENE 63 rilonacept 63 Dual Opioid 63 Sulonex TM 63 CMV vaccine 63 pathophysiological effects 63 HCV NS5B polymerase 63 Anthim 63 pharmacodynamic PD 63 Phase 2a 63 TransVax TM 63 phase 2a 63 P#X# 63 VitiGam TM 63 Presents Preclinical 63 evaluating picoplatin 63 GATTEX TM 63 systemic anaplastic large 63 anticancer therapeutics 63 RhuDex 63 Receives Orphan Drug Designation 63 Tarceva TM 63 preclinical toxicology 63 potently inhibited 63 Rhucin ® recombinant 63 Ridaforolimus 63 vorinostat 63 Fabry Disease 63 Zemplar Capsules 63 PTH analogue 63 JAK2 inhibitor 63 Deforolimus 63 registrational 63 LibiGel ® 63 vascular disrupting agents 63 Glypromate 63 trastuzumab Herceptin R 63 ORENCIA R 63 BENLYSTA ™ 63 Vidaza azacitidine 63 AERx ® 63 Scil Proteins 63 sorafenib Nexavar 63 Eculizumab 63 skeletal metastases 63 GMX# 63 mTOR kinase 63 LEUKINE 63 EndoTAG TM 63 ZFP Therapeutics 63 TRANSDUR ® 63 alpha#beta# integrin 63 Locked Nucleic Acid LNA 63 pharmacological chaperone 63 luteinizing hormone releasing 63 IMiDs ® 63 reslizumab 63 interleukin IL -# 63 velafermin belinostat 63 fusion enhancers 63 RIGScan CR 63 Prostate AdenoCarcinoma Treatment 63 Randomized Phase 63 Preclinical studies suggest 63 Tarvacin Anti Cancer 63 XL# inhibits 63 anti EGFR antibody 63 bazedoxifene conjugated estrogens 63 custirsen 63 LHRH antagonists 63 Oral Calcitonin 63 Azixa 63 aerosolized KL4 surfactant 63 phase IIb III 63 gemcitabine Gemzar ® 63 BrachySil ™ 63 Exelixis XL# 63 R vitespen 63 nucleoside analog 63 Talactoferrin 63 Imetelstat 63 Degarelix 63 DP VPA 63 Troxatyl 63 zanolimumab 63 CXB# 63 sodium Injection 63 CYC# 63 Guanilib 63 EVIZON TM squalamine lactate 63 LE SN# 63 ProLindac 63 papillary renal cell carcinoma 63 MEK Inhibitor 63 Cleviprex TM clevidipine 63 Genasense R oblimersen 63 Phase IIb Clinical Trial 63 untreated metastatic melanoma 63 OMNARIS HFA 63 Cotara 63 selective orally bioavailable 63 defensin mimetic antibiotic 63 Oral NKTR 63 personalized immunotherapy 63 potent suppressor 63 PROSTVAC TM 63 vinorelbine tartrate 63 peripherally acting 63 subcutaneous formulation 63 Hsp# inhibition 63 TRAIL receptor antibody 63 polycythemia vera essential thrombocythemia 63 AFREZZA TM 63 GRNCM1 63 brentuximab vedotin SGN 63 Alzhemed TM 63 biomarker identification 63 eritoran 63 Allovectin 7 ® 63 Panzem ® 63 dose escalation clinical 63 JAK Inhibitor 63 Pivotal Trials 63 alpha folate receptor 63 Mycophenolate Mofetil 63 REG1 Anticoagulation System 63 HDL Mimetic Peptide 63 Vivecon 63 efaproxiral 63 Onalta TM 63 NeuroSTAT ® 63 castrate resistant prostate cancer 63 AMPK activators 63 confirmatory clinical 63 Rhucin R 63 BiTE antibodies targeting 63 bortezomib Velcade 63 intravesical infusion therapy 63 Initiated Phase 63 histamine dihydrochloride 63 Muraglitazar 63 recurrent glioma 63 volociximab 63 mecarbil 63 VA# [002] 63 Vicriviroc 63 Litx 63 INCB# [003] 63 MelaFind R 63 Trastuzumab DM1 63 IMP# 63 Tumor Response 63 glucagon receptor 63 Granulocyte Colony Stimulating Factor 63 IAP inhibitors 63 serine protease inhibitor CU# 63 JAK#/JAK# inhibitor CYT# 63 REP# 63 investigational therapies 63 BLP# Liposome Vaccine 63 NEUMUNE 63 novel DACH platinum 63 ROTARIX 63 MMP inhibitors 63 ISTODAX 63 Urocortin 2 63 Prolongs Survival 63 TRISENOX 63 HCV protease inhibitor 63 SIR Spheres 63 therapeutic monoclonal antibodies 63 novel immunotherapies 63 Triapine 63 molecular imaging radiopharmaceutical 63 TKM Ebola 63 AE# vaccine 63 Plenaxis TM 63 GSK# [002] 63 CYT# 63 placebo controlled Phase 63 dose cohort 63 Unit Dose Budesonide 63 cisplatin gemcitabine 63 DermaPrep 63 refractory prostate cancer 62 Yondelis ® 62 HER2 positive metastatic breast 62 STRIDE PD 62 angiogenesis inhibitor 62 AzaSite Plus 62 prostone 62 vernakalant hydrochloride 62 dependent kinase inhibitor 62 rNAPc2 62 novel orally bioavailable 62 p# inhibitor 62 Interferon Beta 62 Cotara R 62 candidates bavituximab 62 leukotriene pathway 62 octreotide implant 62 darapladib 62 compound AEOL # 62 E1 INT TM 62 Hematide TM 62 omega interferon 62 H#N# VLP vaccine 62 XL# XL# 62 acute peripheral arterial 62 recombinant biopharmaceutical 62 rhIGFBP 3 62 ZADAXIN ® 62 Tezampanel 62 MORAb 62 transmucosal delivery system 62 cytokine refractory 62 Begins Dosing 62 #ME# 62 investigational hepatitis C 62 Azedra ™ 62 midstage studies 62 tesetaxel 62 arsenic trioxide injection 62 Raptiva R 62 Telatinib 62 tiuxetan 62 TransVax ™ 62 lapatinib Tykerb 62 Lenocta 62 intravesical instillation 62 JZP 62 vaccines oncolytic virus 62 epithelial tumors 62 Randomized Phase II 62 INOmax R 62 Recombinant Human 62 Cotara ® 62 dasatinib Sprycel 62 CYT# vascular disrupting 62 Davanat 62 oxypurinol 62 Spiegelmer ® 62 hematological indications 62 RELOVAIR ™ 62 IMPACT DCM 62 siRNA therapeutic 62 IMGN# 62 investigational HCV polymerase 62 Androxal TM 62 omacetaxine 62 XmAb ® 62 chimeric monoclonal antibody 62 vaginally administered lidocaine 62 RNAi therapeutic targeting 62 ProSavin 62 randomized controlled Phase 62 DOR# 62 ZK EPO 62 oral Janus kinase 62 lintuzumab 62 Enzyme Replacement Therapy 62 GVAX R 62 Progenta TM 62 Phase III Trials 62 Phase IIb Trial 62 Crofelemer budesonide foam 62 REOLYSIN ® 62 Hedgehog antagonist 62 ARIKACE 62 Cardio Vascu Grow 62 AVN# [001] 62 humanized monoclonal 62 RNA antagonist 62 targeting CD# 62 lomitapide 62 Intarcia